|
Montréal, Québec, April 8th, 2009 /CNW/ - Aptilon Corporation (the "Corporation") (TSX Venture Exchange: APZ), a leader in multi-channel access to physicians for pharmaceutical marketing programs, today announced that it has taken major steps forward in its business performance over the last six months. The company has renewed contracts for 2009 with its existing roster of top ten US pharmaceutical clients for an approximate total of USD $6.3 million (CAD $7.5 million), successfully moving several clients from first stage engagements to enterprise-level rollouts. In the first quarter, the company also signed contracts for five additional pharmaceutical brands for an approximate total of USD $1.2 million (CAD $1.5 million).
As part of its three-prong approach to grow through alliances as well as organically and by acquisition, Aptilon has also begun collaborative projects with two major health information companies. To capitalize on this business potential, Aptilon has released AxcelRxSM RepCentral, the latest version of its award-winning live video detailing platform that enables pharmaceutical sales representatives to connect with healthcare professionals. Industry research leader Gartner has cited Aptilon as a "2009 Cool Vendor" for this development. Said analyst Dale Hagemeyer, "Aptilon isn't so much a technology offering as it is a technology applied to a specific industry problem in a way that embodies how reps and practitioners interact. The result is greater overall access to the practitioner, for a longer duration each time, and with greater impact."
"Aptilon has successfully negotiated the transition from starter projects on a limited software platform to major, ongoing work with top US pharmaceutical and marketing companies based on leading technology in our field," said Roger Korman, Chairman and CEO of Aptilon. "In addition, we have developed a network of business relationships with major service providers in the health care marketing arena that will yield direct benefits to our business in 2009 and beyond. Together, our current clients and partners provide a solid base for the company to grow in the future."
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with more than 450,000 US physicians via the Internet through its innovative AxcelRxSM Live video detailing platform which hosts promotional, peer selling and other sales and marketing programs. Top ten US pharmaceutical companies have adopted Aptilon's AxcelRx solution to reach leading physicians. Aptilon provides the infrastructure necessary for pharmaceutical companies to build physician awareness, understanding, and product preference during all stages of a product's life cycle, from pre-launch education through end stage support. For more information, visit www.aptilon.com.
AxcelRxSM and ReachNetSM are service marks of Aptilon Corporation.
Forward-looking statements
This news release may contain forward-looking information. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
|
